Growth Metrics

Lineage Cell Therapeutics (LCTX) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Lineage Cell Therapeutics (LCTX) over the last 6 years, with Q4 2016 value amounting to $2.9 million.

  • Lineage Cell Therapeutics' Treasury Shares fell 8396.83% to $2.9 million in Q4 2016 from the same period last year, while for Dec 2016 it was $2.9 million, marking a year-over-year decrease of 8396.83%. This contributed to the annual value of $2.9 million for FY2016, which is 8396.83% down from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Treasury Shares of $334000.0 as of Q3 2025, which was down 3333.33% from $334000.0 recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Treasury Shares ranged from a high of $939000.0 in Q4 2022 and a low of $334000.0 during Q1 2025
  • For the 4-year period, Lineage Cell Therapeutics' Treasury Shares averaged around $537200.0, with its median value being $501000.0 (2024).
  • Its Treasury Shares has fluctuated over the past 5 years, first soared by 41381.39% in 2013, then crashed by 8546.51% in 2016.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' Treasury Shares stood at $8.4 million in 2012, then surged by 413.81% to $43.0 million in 2013, then plummeted by 53.78% to $19.9 million in 2014, then fell by 9.34% to $18.0 million in 2015, then tumbled by 83.97% to $2.9 million in 2016.
  • Its Treasury Shares was $2.9 million in Q4 2016, compared to $2.9 million in Q3 2016 and $2.9 million in Q2 2016.